DEP® irinotecan outperforms irinotecan in multiple cancer models

6 June 2017

Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its proprietary DEP® irinotecan has demonstrated significantly better anti‑tumour activity and increased survival compared with irinotecan in a variety of human colon cancer models. 

  • Starpharma’s DEP® irinotecan significantly outperforms Camptosar® (irinotecan) in multiple human colon cancer models
  • DEP® irinotecan targets colorectal cancer - a significant unmet need and attractive market
  • Further development activities for DEP® irinotecan now underway

Read More

© Starpharma Holdings Limited 2017